Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
  2. Corresponding author: Kevin Y. Xu, MD, MPH, Department of Psychiatry, Washington University School of Medicine, 420 South Euclid Ave, Campus Box 8134, St Louis, MO 63110 ([email protected]).
  3. Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
  4. Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
  5. Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
  6. Alvin J. Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St Louis, Missouri
  7. Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
  8. Departments of Family and Community Medicine and Health and Outcomes Research, St Louis University, St Louis, Missouri
  1. Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14–20. PubMed CrossRef
  2. Goodwin RD, Moeller SJ, Zhu J, et al. The potential role of cocaine and heroin co-use in the opioid epidemic in the United States. Addict Behav. 2021;113:106680. PubMed CrossRef
  3. Daniulaityte R, Silverstein SM, Crawford TN, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern US city. Subst Use Misuse. 2020;55(11):1781–1789. PubMed CrossRef
  4. McCall Jones C, Baldwin GT, Compton WM. Recent Increases in cocaine-related overdose deaths and the role of opioids. Am J Public Health. 2017;107(3):430–432. PubMed CrossRef
  5. Rodríguez-Cintas L, Daigre C, Grau-López L, et al. Impulsivity and addiction severity in cocaine and opioid dependent patients. Addict Behav. 2016;58:104–109. PubMed CrossRef
  6. The Lancet. Opioids and methamphetamine: a tale of two crises. Lancet. 2018;391(10122):713. PubMed CrossRef
  7. Tsui JI, Mayfield J, Speaker EC, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80–85. PubMed CrossRef
  8. Alexander PD, Gicas KM, Willi TS, et al. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology (Berl). 2017;234(9-10):1535–1547. PubMed CrossRef
  9. Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010;105(6):991–1002. PubMed CrossRef
  10. Marzuk PM, Tardiff K, Leon AC, et al. Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med. 1995;332(26):1753–1757. PubMed CrossRef
  11. Tominaga GT, Garcia G, Dzierba A, et al. Toll of methamphetamine on the trauma system. Arch Surg. 2004;139(8):844–847. PubMed CrossRef
  12. Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140–153. PubMed CrossRef
  13. Ahmadi J, Razeghian Jahromi L. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial. Trials. 2017;18(1):259. PubMed CrossRef
  14. Ling W, Hillhouse MP, Saxon AJ, et al. Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. Addiction. 2016;111(8):1416–1427. PubMed CrossRef
  15. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry. 1997;54(8):713–720. PubMed CrossRef
  16. Coffin PO, Santos GM, Hern J, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2020;77(3):246–255. PubMed CrossRef
  17. Siefried KJ, Acheson LS, Lintzeris N, et al. Pharmacological treatment of methamphetamine/amphetamine dependence: a systematic review. CNS Drugs. 2020;34(4):337–365. PubMed CrossRef
  18. Allison P, Christakis N. Fixed-effects methods for the analysis of nonrepeated events. Sociol Methodol. 2006;36(1):155–172. CrossRef
  19. Xu KY, Borodovsky JT, Presnall N, et al. Association between benzodiazepine or z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: a case-crossover analysis. Am J Psychiatry. 2021;178(7):651–659. PubMed CrossRef
  20. Xu KY, Presnall N, Mintz CM, et al. Association of opioid use disorder treatment with alcohol-related acute events. JAMA Netw Open. 2021;4(2):e210061. PubMed CrossRef
  21. Adamson DM, Chang S, Hansen LG. Health Research Data for the Real World: The MarketScan Databases. MedStat; 2006.
  22. Fiellin DA, Weiss L, Botsko M, et al; BHIVES Collaborative. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr. 2011;56(suppl 1):S33–S38. PubMed CrossRef
  23. Salehi M, Emadossadat A, Kheirabadi GR, et al. The effect of buprenorphine on methamphetamine cravings. J Clin Psychopharmacol. 2015;35(6):724–727. PubMed CrossRef
  24. Darke S, Kaye S, Duflou J. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction. 2017;112(12):2191–2201. PubMed CrossRef
  25. Degenhardt L, Sara G, McKetin R, et al. Crystalline methamphetamine use and methamphetamine-related harms in Australia. Drug Alcohol Rev. 2017;36(2):160–170. PubMed CrossRef
  26. Grant KM, LeVan TD, Wells SM, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7(1):113–139. PubMed CrossRef
  27. Zweben JE, Cohen JB, Christian D, et al; Methamphetamine Treatment Project. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181–190. PubMed CrossRef
  28. Michel L, Des Jarlais DC, Duong Thi H, et al; DRIVE Study Team. Intravenous heroin use in Haiphong, Vietnam: Need for comprehensive care including methamphetamine use-related interventions. Drug Alcohol Depend. 2017;179:198–204. PubMed CrossRef
  29. Deck D, Carlson MJ. Access to publicly funded methadone maintenance treatment in two western states. J Behav Health Serv Res. 2004;31(2):164–177. PubMed CrossRef
  30. Morgan JR, Schackman BR, Weinstein ZM, et al. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. Drug Alcohol Depend. 2019;200:34–39. PubMed CrossRef
  31. Kinsky S, Houck PR, Mayes K, et al. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective. J Subst Abuse Treat. 2019;104:15–21. PubMed CrossRef
  32. Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–318. PubMed CrossRef
  33. Philbin MM, Greene ER, Martins SS, et al. Medical, nonmedical, and illegal stimulant use by sexual identity and gender. Am J Prev Med. 2020;59(5):686–696. PubMed CrossRef
  34. Hagle HN, Martin M, Winograd R, et al. Dismantling racism against black, indigenous, and people of color across the substance use continuum: a position statement of the association for multidisciplinary education and research in substance use and addiction. Subst Abus. 2021;42(1):5–12. PubMed CrossRef
  35. Barocas JA. Commentary on Jones et al. (2020): using indirect estimation methods of drug use prevalence to address racial and ethnic health disparities. Addiction. 2020;115(12):2405–2406. PubMed CrossRef
  36. Jones HE, Harris RJ, Downing BC, et al. Estimating the prevalence of problem drug use from drug-related mortality data. Addiction. 2020;115(12):2393–2404. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe